Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

Trial ID or NCT#

NCT01326364

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.

Official Title

Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Dominik Fleischmann
Dominik Fleischmann
Radiologist, Cardiologist
Professor of Radiology (Cardiovascular Imaging)
Jeffrey Norton, MD
Brendan C. Visser, MD
Brendan C. Visser, MD
Hepatobiliary surgeon, Pancreatic surgeon
Professor of Surgery (General Surgery)
R Brooke Jeffrey
George A. Poultsides, MD, MS, FACS
George A. Poultsides, MD, MS, FACS
Hepatobiliary surgeon, Pancreatic surgeon, Liver surgeon, Sarcoma specialist, Gastrointestinal specialist, Minimally invasive surgeon
Professor of Surgery (General Surgery)
George A. Fisher Jr.
George A. Fisher Jr.
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine

Contact us to find out if this trial is right for you.

Contact

ccto-office@stanford.edu
650-498-7061

View on ClinicalTrials.gov